SCHEMBL1465652

SCHEMBL1465652

CCOC(=O)c1cc([N+](=O)[O-])cc([N+](=O)[O-])c1CC

nearest known ligand 0.52

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.51
SMN1; SMN2 Q16637 3/20 0.51
CCR6 P51684 2/20 0.51
MITF O75030 2/20 0.51
POLB P06746 2/20 0.51
LMNA P02545 2/20 0.51
NPC1 O15118 2/20 0.51
GALR2 O43603 1/20 0.51
HSP90AA1 P07900 1/20 0.51
HPGD P15428 1/20 0.51
XBP1 P17861 1/20 0.51
NPSR1 Q6W5P4 1/20 0.51
MAPT P10636 3/20 0.46
KDM4E B2RXH2 1/20 0.44
AKR1B1 P15121 1/20 0.43
KMT2A Q03164 1/20 0.43
GPR35 Q9HC97 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL396778 0.85 NPC1 (0.54) ALDH1A1SMN1; SMN2CCR6MITFPOLB
SCHEMBL9088684 0.84 ALDH1A1 (0.42) ALDH1A1SMN1; SMN2CCR6MITFPOLB
SCHEMBL10877588 0.84 GPR35 (0.55) ALDH1A1SMN1; SMN2CCR6MITFPOLB
SCHEMBL8837568 0.83 ALDH1A1 (0.51) ALDH1A1SMN1; SMN2CCR6MITFPOLB
SCHEMBL11282260 0.83 ALDH1A1 (0.61) ALDH1A1SMN1; SMN2CCR6MITFPOLB
SCHEMBL3475651 0.82 HTT (0.49) ALDH1A1POLBLMNAHPGDNPSR1
SCHEMBL9761593 0.80 NPC1 (0.57) ALDH1A1SMN1; SMN2CCR6MITFPOLB
SCHEMBL14114749 0.79 SMN1; SMN2 (0.61) ALDH1A1SMN1; SMN2CCR6MITFPOLB
SCHEMBL6750268 0.79 SMN1; SMN2 (0.65) ALDH1A1SMN1; SMN2CCR6MITFPOLB
SCHEMBL27733033 0.79 AKR1B1 (0.51) ALDH1A1SMN1; SMN2CCR6MITFPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8623905-B2 Modulators of ATP-binding cassette transporters VERTEX PHARMACEUTICALS INCORPORATED (US) 2014-01-07 US disclosed
US-8575209-B2 Modulators of ATP-binding cassette transporters VERTEX PHARMACEUTICALS INCORPORATED (US) 2013-11-05 US disclosed
US-20110071206-A1 Modulators of ATP-Binding Cassette Transporters VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-03-24 US disclosed
US-20110060024-A1 Modulators of ATP-Binding Cassette Transporters VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-03-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110071206-A1 Modulators of ATP-Binding Cassette Transporters CFTR, ABCB1, ABCC2 ALDH1A1 1961/4885SMN1; SMN2 4738/4885CCR6 1927/4885
US-20110060024-A1 Modulators of ATP-Binding Cassette Transporters CFTR, ABCB1, ABCC2 ALDH1A1 1961/4885SMN1; SMN2 4738/4885CCR6 1927/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.